Search

Your search keyword '"Pergola, Pablo E"' showing total 330 results

Search Constraints

Start Over You searched for: Author "Pergola, Pablo E" Remove constraint Author: "Pergola, Pablo E"
330 results on '"Pergola, Pablo E"'

Search Results

1. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease

2. Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial

5. Cerebral White Matter Hyperintensities, Kidney Function Decline, and Recurrent Stroke After Intensive Blood Pressure Lowering: Results From the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial

6. Cerebral White Matter Hyperintensities, Kidney Function Decline, and Recurrent Stroke After Intensive Blood Pressure Lowering: Results From the Secondary Prevention of Small Subcortical Strokes ( SPS 3) Trial.

7. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease

8. Patterns of blood pressure response during intensive BP lowering and clinical events: results from the secondary prevention of small subcortical strokes trial

10. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics

11. Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease.

15. Efficacy and safety of avenciguat in diabetic and non-diabetic kidney disease: Pooled analysis from two Phase II randomised controlled clinical trials

16. Effect of Avenciguat on Albuminuria in Patients with CKD

19. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

20. Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study

24. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

28. Effects of Bardoxolone Methyl in Alport Syndrome

31. Clinical Features and Racial/Ethnic Differences Among the 3020 Participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial

35. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease

36. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study

39. Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy: A Post Hoc Analysis from the SONAR Trial

41. Authors’ Reply

43. Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD.

45. Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD

48. Effects of Bardoxolone Methyl in Alport Syndrome

49. Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome

Catalog

Books, media, physical & digital resources